How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials

Leading the way is Alnylam Pharmaceuticals, a biotech that has climbed up the industry ranks but is not yet on the same level as the sector’s most successful companies, such as Regeneron or Vertex. An important Phase 3 trial of one of its medicines, Onpattro, is expected to produce results by July. Once seen as a sure bet, the study is now considered a coin toss by investors, according to Paul Matteis, a biotech analyst at Stifel.